Curated News
By: NewsRamp Editorial Staff
December 17, 2025
Trump Poised to Reschedule Cannabis, Acknowledging Medical Use
TLDR
- Companies like Green Thumb Industries could gain tax advantages and market opportunities from cannabis rescheduling to Schedule III.
- The plan shifts cannabis from Schedule I to Schedule III under federal law, formally acknowledging its medical use for the first time.
- Recognizing cannabis's medical benefits federally could improve patient access to treatments and reduce stigma around its therapeutic use.
- Cannabis rescheduling marks a historic shift in U.S. drug policy, potentially transforming both medical access and industry regulations.
Impact - Why it Matters
This news matters because it represents the most significant potential shift in federal cannabis policy in decades, directly affecting millions of patients, a multi-billion dollar industry, and national drug policy. Rescheduling to Schedule III would alleviate crippling tax burdens on state-legal cannabis businesses (saving them an estimated 70% in effective tax rates), potentially lowering consumer prices and accelerating industry growth and investment. For patients, it legitimizes medical cannabis at the federal level, which could improve research access and insurance coverage discussions. However, it does not legalize recreational use federally, creating a new regulatory gray area and leaving state-federal conflicts unresolved for adult-use markets. This move could reshape the legal landscape, influence international drug treaties, and signal a major political evolution on cannabis, impacting everything from banking access to pharmaceutical development.
Summary
In a landmark development for the cannabis industry, President Donald Trump is poised to announce a plan that could fundamentally alter the federal legal status of cannabis. The proposal involves shifting cannabis from Schedule I to Schedule III under the Controlled Substances Act, a move that would mark the first federal acknowledgment of the plant's accepted medical use in the United States. This potential rescheduling promises significant tax relief for cannabis businesses by removing the burdensome Section 280E tax code restrictions, which currently prevent them from deducting standard business expenses. However, the shift also raises new legal and industry concerns, as the reclassification may not equate to full legalization and could introduce fresh regulatory complexities.
The announcement has immediate implications for key players in the burgeoning legal cannabis market, including major companies like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF). As a leading multi-state operator, Green Thumb Industries and similar entities must now scrutinize and potentially adjust their long-term strategies in response to this evolving regulatory landscape. The news originates from CNW420, a daily publication from CannabisNewsWire that provides concise, investor-focused updates on the cannabis sector at 4:20 p.m. Eastern each business day. For those seeking deeper analysis, additional details are available in the full article, which interested readers can access to Read More about the executive order and its ramifications.
This development is part of the fast-changing world of cannabis coverage provided by CannabisNewsWire, a platform powered by IBN that delivers timely industry milestones. The service encourages stakeholders to stay informed through various channels, including SMS alerts by texting CANNABIS to a dedicated number or visiting the CannabisNewsWire website directly. As the industry awaits the formal announcement, this potential policy shift represents a critical juncture, balancing the promise of economic normalization for cannabis companies against the uncertainty of new federal oversight frameworks that will emerge from this historic rescheduling effort.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Trump Poised to Reschedule Cannabis, Acknowledging Medical Use
